Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)
Nab-paclitaxel demonstrated comparable effectiveness to paclitaxel with a lower rate of peripheral neuropathy, suggesting that nab-paclitaxel is an effective treatment option and a relevant comparator for clinical trials of patients with PROC.
Authors
- Darin Dobler
- Robert Louis Coleman (ORCID: https://orcid.org/0000-0001-9343-8754)
- Adrian M. Jubb
- Iulia Cristina Tudor (ORCID: https://orcid.org/0000-0002-4229-2940)
- Prakirthi Yerram (ORCID: https://orcid.org/0000-0001-6042-9077)
- Rachel Myers
- Anju Parthan (ORCID: https://orcid.org/0000-0002-2357-9479)
- Mark S. Shahin (ORCID: https://orcid.org/0000-0003-1910-4523)
- Raina Mathur
- Amanda Kesner-Hays
Institutions
- Corcept Therapeutics (United States) (US)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1016/j.ygyno.2025.11.022
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00